Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Mortality was higher in the RSV cohort, with a 10.1% death rate, compared to 5.5% for flu. RSV infection showed a 52% higher ...

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

Studies have found important benefits from the new RSV immunization and enhanced versions of the flu shot. Plus, the shingles ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older. CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) tod ...